Jazz Pharmaceuticals (JAZZ) Return on Capital Employed (2011 - 2026)

Jazz Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 0.4% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 603.0% year-over-year to 0.4% in Q1 2026; TTM through Mar 2026 was 0.4%, a 603.0% decrease from a year earlier, with the FY2025 full-year figure at 4.48%, down 1120.0% from the prior year.
• Return on Capital Employed climbed to 0.4% in Q1 2026 per JAZZ's latest filing, from 4.64% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 6.46% in Q4 2024 and bottomed at 5.57% in Q3 2025.
• The 5-year median for Return on Capital Employed is 2.0% (2023), against an average of 1.67%.
• Across the five-year window, Return on Capital Employed soared 660 bps in 2023 and sank 1158 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 0.68% in 2022, then surged by 975 bps to 5.93% in 2023, then advanced by 9 bps to 6.46% in 2024, then tumbled by 172 bps to 4.64% in 2025, then jumped by 91 bps to 0.4% in 2026.
• Per Business Quant, the three latest JAZZ Return on Capital Employed figures stand at 0.4% (Q1 2026), 4.64% (Q4 2025), and 5.57% (Q3 2025).